How to Get Jardiance in New York: Prescriptions, Telehealth, Labs, and Pharmacy Guide

What Jardiance Is and Why New York Patients Are Seeking It

Empagliflozin belongs to the SGLT2 inhibitor class and carries FDA approval for three distinct indications: type 2 diabetes mellitus (T2DM) glycemic control, reduction of cardiovascular death in adults with T2DM and established cardiovascular disease, and reduction of hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF). The FDA label also covers a chronic kidney disease (CKD) indication added in 2023. [1]

The cardiovascular evidence behind this drug is not modest. EMPA-REG OUTCOME, published in the New England Journal of Medicine in 2015 (N=7,020), showed that empagliflozin reduced the rate of the primary composite outcome (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) by 14% relative to placebo (hazard ratio 0.86 to 95% CI 0.74 to 0.99, P<0.001 for noninferiority; P=0.04 for superiority) and cut cardiovascular mortality by 38% [2]. That single trial reshaped how cardiologists and endocrinologists approach T2DM with comorbid heart disease.

The EMPEROR-Reduced trial (N=3,730) then demonstrated that empagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 25% in patients with HFrEF regardless of diabetes status (HR 0.75 to 95% CI 0.65 to 0.86, P<0.001) [3]. The EMPA-KIDNEY trial (N=6,609) extended benefit to a broad CKD population, showing a 28% reduction in kidney disease progression or cardiovascular death (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001) [4].

New York's population density, high rate of T2DM (approximately 10.5% of adults according to the CDC), and large cardiology and nephrology specialty base make empagliflozin one of the most frequently prescribed branded agents in the state [5].

Who Can Legally Prescribe Jardiance in New York

Any licensed prescriber with appropriate scope of practice can write a Jardiance prescription in New York. That includes MDs, DOs, nurse practitioners operating under New York's full practice authority statute, and physician assistants working within a supervising physician collaboration agreement.

New York granted nurse practitioners full independent prescriptive authority under the SAVE Act (effective January 1, 2023), which means NPs no longer require a written collaborative practice agreement to prescribe Schedule II through V controlled substances or, importantly, non-controlled medications like empagliflozin [6]. PAs still require a collaboration agreement with a supervising physician, but that agreement does not restrict which medications the PA may prescribe within their scope.

Telehealth prescribers must hold an active New York State license. A prescriber licensed only in another state may not issue a New York Rx unless they hold a special registration or the patient is physically located in a state where that prescriber is also licensed. Patients should confirm their telehealth provider's NY licensure before scheduling.

The American Diabetes Association's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD, an SGLT2 inhibitor with proven benefit should be part of the glucose-lowering regimen independent of baseline HbA1c or individualized HbA1c target." [7] That guideline language has meaningfully expanded the pool of patients who qualify for a prescription beyond those with poor glycemic control alone.

Required Labs Before Starting Empagliflozin in New York

Labs are not optional. The FDA label specifies that empagliflozin is not recommended in patients with an eGFR below 20 mL/min/1.73 m2 (CKD indication) or below 30 mL/min/1.73 m2 (T2DM glycemic indication), so renal function must be confirmed before prescribing [1].

The standard pre-initiation panel most New York clinicians order includes:

Basic Metabolic Panel (BMP). Confirms serum creatinine, potassium, sodium, and bicarbonate. Baseline bicarbonate helps assess risk for euglycemic diabetic ketoacidosis, a rare but serious adverse event reported with SGLT2 inhibitors, particularly during fasting or surgery [8].

eGFR calculated from creatinine (CKD-EPI 2021 equation). This is the gating criterion. KDIGO 2022 guidelines recommend confirming eGFR on two separate occasions at least 90 days apart to stage CKD before initiating SGLT2 therapy [9].

Urine albumin-to-creatinine ratio (UACR). Quantifies proteinuria and helps confirm the CKD indication if applicable. In EMPA-KIDNEY, entry required either eGFR 20 to 44 or eGFR 45 to 89 with UACR 200 to 5 to 000 mg/g [4].

HbA1c. Required for T2DM prescribing documentation and often required by insurers for prior authorization. Target thresholds vary by insurer, but New York Medicaid typically requires HbA1c above 7.0% for T2DM PA approval.

Urinalysis. Screens for active urinary tract infection, which should be treated before starting empagliflozin given the drug's modest increase in genitourinary infection risk [1].

Most New York telehealth platforms order labs through Quest Diagnostics or LabCorp, both of which have patient service centers throughout the five boroughs and across upstate New York. Results typically return within 24 to 72 hours.

A practical pre-prescribing checklist used by the HealthRX clinical team: (1) confirm eGFR meets threshold for intended indication, (2) rule out active UTI on urinalysis, (3) document baseline HbA1c if T2DM indication, (4) verify patient is not planning a prolonged fast or elective surgery within 30 days (hold empagliflozin 3 to 4 days before any procedure requiring general anesthesia per FDA label guidance), and (5) review current diuretic dose to anticipate volume depletion risk in older adults.

How to Get Jardiance Through Telehealth in New York

New York fully permits telehealth prescribing of non-controlled medications, including empagliflozin, under Public Health Law Section 2999-cc. A prescriber may conduct an initial evaluation and write a new prescription via synchronous audio-video visit without a prior in-person examination for non-controlled substances [10].

The practical steps are straightforward. A patient selects a New York-licensed telehealth platform, completes an intake questionnaire covering medical history, current medications, and the target indication, then schedules a video visit. The clinician reviews the intake, orders any missing labs (typically through an at-home kit or local lab order), and writes the Rx once results are back.

Turnaround from first contact to prescription in hand at a retail pharmacy averages 3 to 5 business days when labs are already available. With mail-order delivery from an in-network pharmacy benefit manager (PBM) like Express Scripts or OptumRx, add 2 to 5 additional business days for first fill.

Telehealth platforms operating in New York that prescribe empagliflozin include internal medicine and endocrinology-focused services. Patients should confirm the platform:

• Employs or contracts with a prescriber holding an active New York license
• Orders labs through a CLIA-certified laboratory
• Accepts New York Medicaid or the patient's commercial insurance for the consult fee
• Provides a written visit summary and care plan, required for prior authorization documentation

The New York State Department of Health telehealth guidance specifies that prescribers using audio-only visits (phone without video) may not initiate new prescriptions for patients they have not previously examined [10]. Video capability is required for new Jardiance starts via telehealth.

Prior Authorization for Jardiance in New York: What to Expect

Prior authorization (PA) is the single biggest friction point for New York patients trying to start Jardiance. Both commercial plans and New York Medicaid require PA for empagliflozin in most clinical scenarios outside straightforward T2DM with HbA1c above a plan-specific threshold.

New York Medicaid (Medicaid FFS and managed care plans) covers empagliflozin for T2DM, HFrEF, and CKD with PA. The standard Medicaid PA criteria include:

• Confirmed diagnosis matching an FDA-approved indication
• Documentation of HbA1c above 7.0% for T2DM indication (some plans require above 7.5%)
• For heart failure: echocardiography report confirming LVEF 40% or below
• For CKD: two eGFR values and a UACR result per KDIGO 2022 staging [9]
• Trial of at least one first-line agent (typically metformin for T2DM) unless contraindicated

Commercial insurers in New York, including Empire BlueCross BlueShield, Aetna, UnitedHealthcare, and Cigna, use similar criteria but vary on whether they require a documented metformin trial for the cardiovascular or CKD indication. The American College of Cardiology's 2022 Heart Failure Guidelines note that SGLT2 inhibitors should be initiated without requiring prior failure of other HF agents [11], and many commercial plans have updated PA criteria to reflect this, though Medicaid managed care plans in New York have been slower to align.

PA approval timelines in New York average 3 to 15 business days under routine review. Urgent PA (for patients with active clinical deterioration) must be decided within 72 hours under New York Insurance Law Section 4903 [12].

Patients denied PA have the right to an internal appeal and then an external appeal through the New York State Department of Financial Services. External appeal decisions by an independent organization are binding on the insurer.

Prescribers can reduce PA denial rates by including in the PA packet: the office note documenting the indication, the relevant lab results, the echocardiography report if HF-indicated, and a direct quotation of the ADA 2024 or ACC 2022 guideline supporting the prescription [7][11].

Jardiance Pharmacy Options in New York

Every major retail pharmacy chain in New York dispenses empagliflozin. CVS, Walgreens, Rite Aid (where still operating), Duane Reade, and independent pharmacies throughout the five boroughs and upstate cities all stock the 10 mg and 25 mg tablets. The cash price without insurance runs approximately $550 to $620 per 30-tablet supply at retail [13].

Manufacturer savings programs. Boehringer Ingelheim and Lilly offer the Jardiance Savings Card, which may reduce out-of-pocket cost to as low as $10 per 30-day supply for commercially insured patients. This card is not valid for patients covered by Medicare, Medicaid, or any federal or state government payer [13].

Medicare Part D. Jardiance became subject to the $35 monthly insulin cap provisions of the Inflation Reduction Act for insulin products, but empagliflozin itself is not insulin and is not capped at $35. Under the 2025 Medicare Part D redesign, out-of-pocket spending for all Part D drugs is capped at $2,000 annually. Empagliflozin typically falls in Tier 3 or Tier 4 on most Part D formularies [14].

503A compounding pharmacies in New York. New York-licensed 503A compounding pharmacies may legally compound empagliflozin for individual patients with a valid prescription when there is a documented clinical reason the commercial product does not meet the patient's needs (e.g., a specific dose not available commercially, or a documented excipient allergy to a tablet ingredient). New York's Board of Pharmacy enforces strict compounding standards consistent with USP 795 for non-sterile preparations [15]. These pharmacies may ship within New York State to patients; interstate shipment requires compliance with the receiving state's pharmacy laws.

Mail-order PBM pharmacies. Patients with commercial insurance through Express Scripts, OptumRx, or CVS Caremark can fill a 90-day supply by mail, often at lower copay than retail 30-day fills. First fills at mail-order typically take 7 to 10 business days.

Transferring an Existing Jardiance Prescription to New York

Patients relocating to New York or spending extended time in the state can transfer an existing Jardiance prescription. New York Pharmacy Law permits pharmacists to transfer a prescription for a non-controlled substance between pharmacies once per prescription. The receiving pharmacy contacts the original pharmacy directly.

For patients using a telehealth provider licensed in another state, the prescription cannot simply be redirected to a New York pharmacy. The original prescriber must hold a New York license to write a New York Rx. Patients in this situation should either establish care with a New York-licensed provider or confirm their telehealth provider holds a New York license before relocating.

Medicaid coverage does not automatically transfer across state lines. A patient previously covered by another state's Medicaid plan must enroll in New York Medicaid and obtain a new PA under New York criteria. New York Medicaid enrollment for income-eligible adults is available through NY State of Health, the state's official health plan marketplace [16].

Dosing, Titration, and Monitoring After Starting Jardiance

The standard starting dose is 10 mg once daily, taken in the morning with or without food. After 4 weeks, the prescriber may increase to 25 mg once daily if additional glycemic control is needed and the patient tolerates the 10 mg dose [1]. For the heart failure and CKD indications, 10 mg once daily is the approved and evidence-based dose; titration to 25 mg is not required and was not tested in the landmark HF or CKD trials [3][4].

Monitoring after initiation should include:

• Repeat BMP and eGFR at 4 weeks and then every 3 to 6 months
• HbA1c every 3 months until stable, then every 6 months for T2DM indication
• Blood pressure at each visit (empagliflozin produces a modest systolic BP reduction of approximately 3 to 4 mmHg in clinical trials) [2]
• Symptom inquiry for genital mycotic infections (affecting approximately 6 to 7% of women and 3% of men in EMPA-REG OUTCOME) [2]

The FDA label recommends temporarily discontinuing empagliflozin at least 3 to 4 days before elective surgery or procedures requiring general anesthesia or significant fasting, due to risk of euglycemic DKA [1]. Patients should carry a medication card listing this instruction and share it with any surgical team.

Endocrine Society Clinical Practice Guidelines (2022) state: "SGLT2 inhibitors should be held perioperatively and restarted only after the patient is eating and drinking normally and there is no concern for volume depletion or infection." [17] That guidance aligns with the FDA label and applies to New York clinical practice settings.

Cost Reduction Strategies for New York Patients Without Insurance

Uninsured or underinsured New York patients face the full retail cost of Jardiance, which is among the highest of any oral antidiabetic agent. Several pathways exist to reduce this burden.

Boehringer Ingelheim operates a patient assistance program (Lilly Cares / BI Cares) that provides Jardiance at no cost to uninsured patients who meet income eligibility criteria (typically at or below 400% of the federal poverty level) [18]. Applications require proof of income, a valid prescription, and confirmation of no active insurance coverage.

New York State also runs the Elderly Pharmaceutical Insurance Coverage (EPIC) program for residents aged 65 and older with income below $75,000 (single) or $100,000 (married), which supplements Medicare Part D and reduces out-of-pocket drug costs [16].

GoodRx and similar discount card programs can bring the retail cost of empagliflozin 10 mg (30 tablets) to approximately $450 to $500 at select New York pharmacies, which is still substantially below the list price but represents a meaningful reduction for cash-pay patients. These cards cannot be combined with insurance benefits.

Generic empagliflozin is not yet available in the United States as of mid-2025; Boehringer Ingelheim holds market exclusivity. Patent expiration timelines suggest generic entry may occur by 2025 to 2026 pending FDA approval of ANDA submissions [13].

Special Populations: What New York Clinicians Should Know

Older adults (age 65 and above) represent a significant portion of New York patients being considered for Jardiance, particularly for the HF and CKD indications. Volume depletion is a greater concern in this group. EMPA-REG OUTCOME reported higher rates of volume depletion-related adverse events in patients taking loop diuretics concurrently, and prescribers should consider a diuretic dose reduction of 25 to 50% at Jardiance initiation in diuretic-dependent patients [2][8].

Patients with recurrent urinary tract infections should be counseled on the modest increase in UTI risk with SGLT2 inhibitors and should report symptoms promptly. Patients with a history of Fournier's gangrene (necrotizing fasciitis of the perineum) should not receive SGLT2 inhibitors; the FDA issued a boxed warning on this rare but serious risk in 2018 [1].

Pregnancy is a contraindication. Empagliflozin is FDA Pregnancy Category risk: available data are insufficient to establish drug-associated risk, but animal studies show fetal renal effects. ACOG recommends against SGLT2 inhibitor use in pregnancy [19]. Women of reproductive age in New York who may become pregnant should use effective contraception while taking Jardiance and discontinue the drug as soon as pregnancy is confirmed.